Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: The CARNEBI trial
详细信息    查看全文
文摘

Background

Several ¦Â-blockers, with different pharmacological characteristics, are available for heart failure (HF) treatment. We compared Carvedilol (¦Â1-¦Â2-¦Á-blocker), Bisoprolol (¦Â1-blocker), and Nebivolol (¦Â1-blocker, NO-releasing activity).

Methods

Sixty-one moderate HF patients completed a cross-over randomized trial, receiving, for 2 months each, Carvedilol, Nebivolol, Bisoprolol (25.6 ¡À 12.6, 5.0 ¡À 2.4 and 5.0 ¡À 2.4 mg daily, respectively). At the end of each period, patients underwent: clinical evaluation, laboratory testing, echocardiography, spirometry (including total DLCO and membrane diffusion), O2/CO2 chemoreceptor sensitivity, constant workload, in normoxia and hypoxia (FiO2 = 16 % ), and maximal cardiopulmonary exercise test.

Results

No significant differences were observed for clinical evaluation (NYHA classification, Minnesota questionnaire), laboratory findings (including kidney function and BNP), echocardiography, and lung mechanics. DLCO was lower on Carvedilol (18.3 ¡À 4.8* mL/min/mm Hg) compared to Nebivolol (19.9 ¡À 5.1) and Bisoprolol (20.0 ¡À 5.0) due to membrane diffusion 20 % reduction (* = p < 0.0001). Constant workload exercise showed in hypoxia a faster VO2 kinetic and a lower ventilation with Carvedilol. Peripheral and central sensitivity to CO2 was lower in Carvedilol while response to hypoxia was higher in Bisoprolol. Ventilation efficiency (VE/VCO2 slope) was 26.9 ¡À 4.1* (Carvedilol), 28.8 ¡À 4.0 (Nebivolol), and 29.0 ¡À 4.4 (Bisoprolol). Peak VO2 was 15.8 ¡À 3.6* mL/kg/min (Carvedilol), 16.9 ¡À 4.1 (Nebivolol), and 16.9 ¡À 3.6 (Bisoprolol).

Conclusions

¦Â-Blockers differently affect several cardiopulmonary functions. Lung diffusion and exercise performance, the former likely due to lower interference with ¦Â2-mediated alveolar fluid clearance, were higher in Nebivolol and Bisoprolol. On the other hand, Carvedilol allowed a better ventilation efficiency during exercise, likely via a different chemoreceptor modulation. Results from this study represent the basis for identifying the best match between a specific ¦Â-blocker and a specific HF patient.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700